Why the study?
Guidelines recommend uninterrupted warfarin or direct thrombin inhibitors during AF ablation, but Japanese real-world periprocedural anticoagulation management needed clarification.
Does periprocedural anticoagulation with DTIs reduce periprocedural complications compared to FXa inhibitors in patients undergoing AF ablation?
Does periprocedural anticoagulation with DTIs reduce periprocedural complications compared to FXa inhibitors in patients undergoing AF ablation?
In a large Japanese real-world registry, periprocedural anticoagulation with DTIs during AF ablation was a reasonable regimen to reduce complications compared to FXa inhibitors.
Answers are grounded in this paper and cite their sources.
Supports DTI use in AF ablation; leaves open randomized confirmation of reduced tamponade risk versus FXa inhibitors.
Background: The guidelines recommend anticoagulation management with uninterrupted warfarin or direct thrombin inhibitors (DTIs) during the atrial fibrillation (AF) ablation periprocedural period. Objectives: To clarify the Japanese real-world latest periprocedural anticoagulation management during AF ablation. Methods: This multicenter observational study included 6232 consecutive AF patients (68.7 ± 10.9 years, 4346 men) who underwent periprocedural anticoagulation therapy using direct oral anticoagulants (DOACs) between January 2022 and August 2023. Two patients in the uninterrupted FXaI-group required surgical management for cardiac tamponade. Conclusions: Our multicenter real-world data demonstrated that anticoagulation with DTIs was a reasonable periprocedural anticoagulation regimen to reduce periprocedural complications.
No takes yet. Share an insight, caveat, or question.
Taomoto et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: